文献速递冠心病

急性冠脉综合征临床试验主要假说之外的影响:一项系统综述

Influence of Clinical Trials of Acute Coronary Syndrome Beyond the Primary Hypothesis: A Systematic Review.
PubMed 文献 · JAMA Cardiol · 2020-01-01

该系统综述评估了2005至2009年发表的大型急性冠脉综合征试验的长期影响,发现未达到主要目标的试验主要引用次数较少,但二次分析活动无显著差异,且所有试验均被至少1部临床实践指南引用,表明临床试验的长期重要性不取决于主要结果。

要点

  • 二次分析活动频率在主要试验后5年内达到峰值643次。
  • 所有试验均被至少1部临床实践指南引用,贡献于临床推荐。

核心结论

  • 未达到主要目标的试验主要引用次数较少,但二次分析活动和指南引用无显著差异,临床试验的长期重要性不取决于主要结果。

研究设计与样本

  • 系统综述筛选Cochrane对照试验中心注册库,纳入2005年1月1日至2009年12月31日期间在六种主要期刊发表主要结果、样本量超过1000例的急性冠脉综合征临床试验。

主要发现

  • 共筛选784条记录,纳入25项临床试验的30篇主要发表文献。
  • 截至2018年12月31日,这些试验被引用中位497次(IQR 424-931)。
  • 所有试验均被至少1部临床实践指南引用。

临床怎么用

  • 临床医生应认识到,即使试验未达到主要目标,其长期证据贡献和指南推荐价值仍可能存在。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Conducting a clinical trial involves significant risks, time, and resources. The return on investment for these trials, measured by advancing health care and contributions to the scientific literature, is often uncertain. OBJECTIVE: To assess the long-term effects of major clinical trials of acute coronary syndromes contemporary to the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial, which did not achieve its primary objective. EVIDENCE REVIEW: The Cochrane Central Register of Controlled Trials database was screened for clinical trials of acute coronary syndromes (including unstable angina, ST-elevation myocardial infarction, and non-ST-elevation myocardial infarction) with more than 1000 participants and primary results published between January 1, 2005, and December 31, 2009, in Circulation, European Heart Journal, JAMA, Journal of the American College of Cardiology, The Lancet, and The New England Journal of Medicine. For identified trials, bibliographic information, citations, trial name, registration, inclusion diagnosis, intervention type, sample size, primary outcome result, sponsor information, and academic involvement were extracted. To identify secondary analyses, bibliographic information for citing articles, their citations, and their abstracts were extracted. Clinical practice guideline bibliographies for citations of trial publications were reviewed, and the class and level of evidence of resulting recommendations were extracted. FINDINGS: Of 784 records screened, 30 were primary publications of 25 clinical trials. Through December 31, 2018, these trials were cited a median of 497 times (interquartile range [IQR], 424-931 citations). Trials that did not achieve their primary objective had fewer primary citations (the number of times that each published journal article with the primary [main] results of a trial was cited) (median, 443 [IQR, 396-468] vs 868 [IQR, 645-1774] citations, P = .006). The frequency of secondary analyses peaked within 5 years of the primary trial at 643. Trials that did not achieve the primary objective had fewer secondary analyses (median, 15 [IQR, 5-31] vs 18 [IQR, 10-43] analyses, P = .44) that were not cited significantly less often (median, 484 [IQR, 191-1299] vs 1124 [IQR, 410-4283] citations, P = .16). All trials were cited by at least 1 clinical practice guideline. CONCLUSIONS AND RELEVANCE: This review found that trials that achieved the primary objective were frequently cited. Secondary research activity did not differ by primary result, and the primary trials and secondary analyses contributed to clinical practice recommendations. These data show the long-term importance of clinical trials regardless of primary outcome result.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Luoma LM, Westerhout CM, Granger CB, et al. Influence of Clinical Trials of Acute Coronary Syndrome Beyond the Primary Hypothesis: A Systematic Review. JAMA Cardiol. 2020. PMID: 32745162. doi:10.1001/jamacardio.2020.2855

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。